SHARPE
Reported results
- Net sales were $647.7 million for the third quarter of 2026.
- Gross margin was 33.4% for the third quarter of 2026.
- Income from operations (GAAP) was $115.1 million; adjusted income from operations (non-GAAP) was $118.8 million.
- Net income attributable to Gentex (GAAP) was $90.6 million; adjusted net income attributable to Gentex (non-GAAP) was $97.8 million.
- Earnings per diluted share attributable to Gentex (GAAP) were $0.43; adjusted earnings per diluted share (non-GAAP) were $0.47.
Guidance
- Full-year 2026 consolidated revenue is expected to be approximately $2.65 billion.
- Full-year 2026 gross margin is expected to be between 34.0% – 34.5%.
- Full-year 2026 operating expenses (excluding severance and impairments) are expected to be $395 – $410 million.
- Full-year 2026 tax rate is expected to be 16% – 16.5%.
- Full-year 2026 capital expenditures are expected to be $100 – $115 million.
- Full-year 2026 depreciation & amortization is expected to be $100 – $105 million.
- Maintaining 2027 revenue guidance of $2.80 billion to $2.90 billion.
Notes
Beginning in the first quarter of 2026, the Company revised its non-GAAP presentation to include Adjusted Other (Loss) Income, conforming prior-period non-GAAP measures to the current presentation.
Price and volatility reaction
The stock moved -5.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.6 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 21.74 | 2026-10-22 |
| Close after release | 20.66 | 2026-10-23 |
| Realised move | -5.0% | close to close |
| 30d ATM IV change | -4.6 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-23 (8-K, Item 2.02). Read the original filing on sec.gov.